Pharmaceutical Executive March 10, 2025
Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma.
Sun Pharma announced that it has agreed to terms on the acquisition of Checkpoint Therapeutics, an immunotherapy and targeted oncology company, for approximately $355 million. The acquisition includes Unloxcyt (cosibelimab-ipdl), Checkpoint’s FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma (cSCC).1
“Combining Unloxcyt, an FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma, with Sun Pharma’s global presence means patients with cSCC may soon have access to an important new treatment option. The acquisition further bolsters our innovative portfolio in onco-derm therapy,” said Dilip Shanghvi, chairman, managing director, Sun Pharma, in a press release.
Under the...
Today's Sponsors
Today's Sponsor